چاپ صفحه |  صفحه نخست سامانه |  چکیده مقاله |  نویسندگان |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| Uterine serous carcinoma (USC) in association with endometrial clear cell carcinoma (CCC) and grade 3 endometrioid carcinoma is responsible for 70-75% of endometrial carcinoma deaths and per se accounts for 39% of this cancer related mortality. Its tendency for early spread, leads to upstaging of 50-70% of clinically stage I cancers at the time of operation. Involved molecular pathway(s) in this cancer differ from those of conventional endometriod carcinoma. It has been accepted that P53 mutation occurs as an early event in the endometrial serous carcinogenesis. Findings of P53 signature in the endometrial polyps and minor epithelial atypia (Endometrial Glandular DysplasiaEmGD) supported this assumption that mutation in PT53 may develop before apparent morphologic atypia (p53 signature), or occur in pre-existing malignant lesions of endometrium such as high grade endometriod carcinoma. Early detection through minimally-invasive approaches appears to be the gold strategy decreasing the uterine serous carcinoma related mortality. During last decades researchers have been interested in discriminating the specific and sensitive biomarkers such as microRNAs for early detection of invasive cancers. These recently explained microRNAs can be useful in monitoring the tumor response against different therapeutic agents as well as in tracing of disease process. In this review firstly we will concentrate on clinical aspects of uterine serous carcinoma and the essential molecular pathways of serous carcinogenesis .Then the main microRNAs involved in development of this cancer comprehensively will be discussed. |
| نویسنده | نفر چندم مقاله |
|---|---|
| علی دسترنج تبریزی | اول |
| لیلا کفشدوز پورپل سنگی | سوم |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| JGWH.MS.ID.555710 (1).pdf | 1398/06/07 | 759718 | دانلود |
